{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:11:44Z","timestamp":1787238704839,"version":"build-2736575974"},"reference-count":40,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2008,7,10]],"date-time":"2008-07-10T00:00:00Z","timestamp":1215648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2008,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Preclinical evidence supports the role of estrogen receptor signaling in prostate cancer. In this trial we investigated the tolerability and efficacy of fulvestrant, a pure estrogen receptor antagonist, in the treatment of castration resistant prostate cancer (CRPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Patients with CRPC were enrolled after written informed consent. Fulvestrant was administered by intramuscular injection at a dose of 500 mg on day 0, then 250 mg on day 14, day 28 and monthly thereafter. History, physical examination, serum prostate specific antigen (PSA) levels and toxicity was evaluated monthly. Radiographic studies were repeated every 3 months to assess disease. Treatment was continued until disease progression, unacceptable toxicity, non\u2010compliance or consent withdrawal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Twenty patients were enrolled over a period of six months. All patients were Caucasians with median age of 69.5 years [range: 47\u201385 years]. Sixteen patients (80%) had radiological evidence of metastasis and four patients (20%) had rising PSA as the only evidence of progressive disease. Patients received a median of three treatment cycles of fulvestrant [range: 1\u201311]. Median time to progression was 4.3 months (95% confidence interval of 3\u20135.7 months) and median overall survival was 19.4 months (range: 9.9\u201319.4 months) after a median follow\u2010up of 16 months. No patient showed \u226550% reduction in PSA or radiologic improvement. Few adverse events were noted, none of which were attributed directly to fulvestrant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Fulvestrant was well tolerated but failed to produce clinical or PSA response in men with CRPC. Prostate 68: 1461\u20131466, 2008. \u00a9 2008 Wiley\u2010Liss, Inc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pros.20813","type":"journal-article","created":{"date-parts":[[2008,7,10]],"date-time":"2008-07-10T14:42:21Z","timestamp":1215700941000},"page":"1461-1466","source":"Crossref","is-referenced-by-count":27,"title":["Phase II study of fulvestrant (faslodex\u00ae) in castration resistant prostate cancer"],"prefix":"10.1002","volume":"68","author":[{"given":"Manpreet K.","family":"Chadha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umeer","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Silliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Escott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valencia","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"Trump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,10]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.579"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.021"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01633-3"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"issue":"1","key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cncr.20726","article-title":"Society of urologic oncology position statement: Redefining the management of hormone\u2010refractory prostate carcinoma","volume":"103","author":"Chang SS","journal-title":"Cancer"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000158449.83022.40"},{"issue":"2","key":"e_1_2_1_8_2","first-page":"185","article-title":"Hormone\u2010refractory prostate cancer: Choosing the appropriate treatment option","volume":"21","author":"Ross RW","year":"2007","journal-title":"Oncology (Williston Park)"},{"issue":"4","key":"e_1_2_1_9_2","first-page":"CD005247","article-title":"Chemotherapy for hormone\u2010refractory prostate cancer","volume":"18","author":"Shelley M","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/35094009"},{"key":"e_1_2_1_11_2","first-page":"3175","article-title":"Expression of estrogen receptor (ER)\u2010a and ER\u2010b in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation","volume":"60","author":"Kin\u2010Mang L","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20585"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)61666-5"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.5.2051"},{"issue":"14","key":"e_1_2_1_15_2","first-page":"5331","article-title":"Frequent loss of estrogen receptor\u2010beta expression in prostate cancer","volume":"61","author":"Horvath LG","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10171"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1013303414460"},{"key":"e_1_2_1_18_2","first-page":"165","article-title":"Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies","volume":"7","author":"Byar DP","year":"1988","journal-title":"NCI Monogr"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00173-3"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.13.908"},{"issue":"13","key":"e_1_2_1_21_2","first-page":"3649","article-title":"Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen\u2010responsive human prostate cancer cell line LNCaP through an androgen\u2010independent pathway","volume":"62","author":"Kim IY","year":"2002","journal-title":"Cancer Res"},{"issue":"18","key":"e_1_2_1_22_2","first-page":"5365","article-title":"Raloxifene, a mixed estrogen agonist\/antagonist, induces apoptosis in androgen\u2010independent human prostate cancer cell lines","volume":"62","author":"Kim IY","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.05974.x"},{"issue":"5","key":"e_1_2_1_24_2","first-page":"1370","article-title":"Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model","volume":"62","author":"Raghow S","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6"},{"key":"e_1_2_1_26_2","first-page":"3867","article-title":"A potent specific pure antiestrogen with clinical potential","volume":"51","author":"Wakeling AE","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.9.4037"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.106.4.1377"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00353.2001"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1593\/neo.05853"},{"issue":"12","key":"e_1_2_1_31_2","first-page":"3175","article-title":"Expression of estrogen receptor (ER)\u2010alpha and ER\u2010beta in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation","volume":"60","author":"Lau KM","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/35094009"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-7152(02)00436-4"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2004.03.004"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443080-00003"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-7-774"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3461"},{"key":"e_1_2_1_40_2","first-page":"6739","article-title":"Comparison of the short\u2010term biological effects of 7alpha\u2010[9\u2010(4,4,5,5,5\u2010pentafluoropentylsulfinyl)\u2010nonyl]estra\u20101,3,5, (10)\u2010triene\u20103,17 beta\u2010diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer","volume":"61","author":"Robertson JF","year":"2001","journal-title":"Cancer Res"},{"issue":"1","key":"e_1_2_1_41_2","first-page":"S177","article-title":"Effects of fulvestrant on estrogen receptor levels during long\u2010term treatment of patients with advanced breast cancer\u2014Final results","volume":"88","author":"Gutteridge E","year":"2004","journal-title":"Breast Cancer Res Treat"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.20813","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.20813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T12:20:38Z","timestamp":1699964438000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.20813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,10]]},"references-count":40,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2008,9,15]]}},"alternative-id":["10.1002\/pros.20813"],"URL":"https:\/\/doi.org\/10.1002\/pros.20813","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,10]]}}}